Gene and Cell Therapy for Thrombosis, AIDS and Inherited Disorders

Share Article

An American Society of Gene & Cell Therapy (ASGCT) Media Event taking place in Washington, DC, on Wednesday, May 21, 2014, from 10:45 am – 12:15 pm will feature academic and industry leaders in gene and cell therapy.

The event will profile exciting clinical trial results in patients suffering from serious and often fatal diseases such as human immunodeficiency virus (HIV), Inherited Immunodeficiencies, Hemophilia B, and complications from Thrombosis.

There will be a Media Event in Washington, DC, on Wednesday, May 21, 2014, from 10:45 am – 12:15 pm in Wilson A of the Marriott Wardman Park Hotel, which is sponsored by the American Society of Gene & Cell Therapy (ASGCT).

The event will profile exciting clinical trial results in patients suffering from serious and often fatal diseases such as human immunodeficiency virus (HIV), Inherited Immunodeficiencies, Hemophilia B, and complications from Thrombosis. All registered media will have the opportunity for personal, one-on-one questions with academic and industry leaders in the field, including:

Dr. Bruce L. Levine of the University of Pennsylvania is developing a gene and cell therapy strategy to achieve a “functional cure” for HIV infection by genome editing of cells, and results from the first-in-human trial of this novel treatment strategy will be presented.

Professor Adrian Thrasher of the University College of London’s Institute of Child Health will discuss the impressive results of recent advances in gene therapy technology to treat inherited immunodeficiencies in patients, many of whom are children.

Researchers at St. Jude Children's Research Hospital have successfully treated Hemophilia patients with gene therapy that led to their disease-free living for several years. Dr. Andrew Davidoff will provide the latest update on these exciting clinical results.

Thrombosis, or the formation of blood clots inside a blood vessel, remains the major cause of death and disability in the western world. Dr. Bruce Sullenger of Duke University Medical Center will describe the recent development of gene and cell therapy strategies to control thrombosis that is currently in a Phase 3 clinical trial.

The media event will take place in Wilson A in the Marriott Wardman Park Hotel.

Members of the media are welcome to conduct individual interviews with each speaker following the presentation, and will receive complimentary full-access registration to the ASGCT 17th Annual Meeting. Representatives who wish to attend may contact ASGCT directly at 414.278.1341 or mdean(at)asgct(dot)org.

The American Society of Gene & Cell Therapy (ASGCT) is a professional nonprofit medical and scientific organization dedicated to the understanding, development and application of genetic and cellular therapies and the promotion of professional and public education in the field. For more information on ASGCT, visit its website, http://www.asgct.org.

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Alicia Sukup
Executive Director Inc.
+1 (414) 918-3156
Email >
Visit website